Adebrelimab Injection

DRUG13 trials

Sponsors

Yunpeng Liu, Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai Zhongshan Hospital, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Peking University Cancer Hospital & Institute

Conditions

Advanced Biliary Tract CancerAdvanced Solid TumorsAdvanced Urothelial CarcinomaAdvanced or Metastatic Non-small Cell Lung CancerColorectal CancerEsophageal Squamous Cell Carcinoma (ESCC)Gastric CancerGastroesophageal-junction Cancer

Phase 1

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

RecruitingNCT06512051

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced or Metastatic Non-small Cell Lung Cancer

Start: 2024-07-30End: 2026-10-31Target: 248Updated: 2025-12-23

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

RecruitingNCT06639347

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Urothelial Carcinoma

Start: 2024-11-04End: 2027-05-31Target: 90Updated: 2024-11-18

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

RecruitingNCT06703177

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Advanced Solid Tumors

Start: 2025-02-18End: 2027-07-01Target: 876Updated: 2025-12-03

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

RecruitingNCT06840002

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Ovarian Cancer

Start: 2025-03-18End: 2026-07-31Target: 150Updated: 2025-09-30

Phase 2

Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer

Not yet recruitingNCT06599775

Shanghai Zhongshan HospitalResectable Esophageal Squamous Cell Carcinoma

Start: 2024-10-31End: 2028-10-31Target: 42Updated: 2024-09-19

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

RecruitingNCT07071714

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Colorectal Cancer

Start: 2025-07-22End: 2031-10-01Target: 200Updated: 2026-03-18

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

RecruitingNCT07110571

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Gastric Cancer, Gastroesophageal-junction Cancer

Start: 2025-08-28End: 2027-05-31Target: 200Updated: 2026-01-09

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

Not yet recruitingNCT07357532

Peking University Cancer Hospital & InstituteSmall Cell Lung Carcinoma

Start: 2026-01-31End: 2028-10-30Target: 44Updated: 2026-01-22

Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT07638436

Sun Yat-sen UniversityEsophageal Squamous Cell Carcinoma (ESCC)

Start: 2026-06-17End: 2028-01-31Target: 42Updated: 2026-06-10

A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma

Not yet recruitingNCT07682272

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk

Start: 2026-07-01End: 2029-07-01Target: 120Updated: 2026-07-02

Phase 3

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

RecruitingNCT07229625

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Advanced Biliary Tract Cancer

Start: 2026-01-21End: 2029-12-01Target: 604Updated: 2026-01-28

A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer

Not yet recruitingNCT07679360

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Triple Negative Breast Cancer

Start: 2026-07-01End: 2032-12-01Target: 1000Updated: 2026-07-01

Unknown Phase

Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

RecruitingNCT06480864

Yunpeng LiuSmall Cell Lung Cancer

Start: 2024-08-09End: 2026-08-31Target: 38Updated: 2025-01-06

Related Papers

Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with adebrelimab plus chemotherapy (CLOG2402-ADAPT): A multi-center, single-arm, phase II trial.

Journal of Clinical Oncology2026-06-23

SHR-A2102 in combination with adebrelimab as first-line treatment in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC): Results from a phase 1b/2 study.

Journal of Clinical Oncology2026-05-28